journal of men's health
Volume 5 , Pages S26-S34 , September 2008

Clinical awareness and diagnosis of male hypogonadism

References 

  1. Nieshlag E, Behre HM, Bouchard P, Corrales J, Jones TH, Stalla G, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update. 2004;10:409–419
  2. Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legos JJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM and EAU recommendations. J Androl. 2006;27:135–137
  3. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with Type 2 diabetes. Eur J Endocrinol. 2006;154:899–906
  4. Malkin CJ, Pugh PJ, Kapoor D, Jones RD, Channer KS, Jones TH, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313–3318
  5. Webb CM, McNeill JG, Hayward CS, deZeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100:1690–1696
  6. English KM, Steeds RP, Diver MJ, Jones TH, Channer KS. Low dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. Circulation. 2000;102:1906–1911
  7. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006;27:54–56
  8. Jones TH. Testosterone associations with erectile dysfunction diabetes and the metabolic syndrome. Eur Urol (suppl). 2007;6:847–857
  9. Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, et al. Free testosterone and risk for Alzheimer's disease in older men. Neurology. 2004;62:188–193
  10. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166:1660–1665
  11. Laughlin GA, Barrett-Connor E, Bergstrom J. Low testosterone and mortality in older men. J Clin Endocrinol Metab. 2007;epub ahead of print
  12. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause mortality and cause-specific mortality in men. Arch Int Med. 2007;167:1252–1260
  13. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto A, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society Clinical Practise Guideline. J Clin Endocrinol Metab. 2006;91:1995–2010
  14. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239–1242
  15. Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C. A new aging males’ symptoms rating scale. Aging Male. 1999;2:105–114
  16. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. position statement: utility,limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92:405–413
  17. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for estimation of free testosterone in serum. J Clin End Metab. 1999;84:3666–3672
  18. de Ronde W, van der Schouw YT, Pols HA, Gooren LJ, Muller M, Grobbee DE, et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clinical Chemistry. 2006;52:1777–1784
  19. Morris PD, Malkin CJ, Channer KS, Jones TH. A mathematical comparison of techniques to predict biologically active testosterone in a cohort of 1072 men. Eur J Endocrinol. 2004;151:241–249
  20. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-resonse relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281:E1172–E1181
  21. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:1966–1972
  22. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB, et al. Testosterone, sex hormone binding globulin and the development of Type 2 diabetes in middle aged men: prospective results form the Massachusetts Male Aging Study. Diabetes Care. 2000;23(4):490–494
  23. Haffner SM, Shaten J, Stern MP, Katz MS. Low levels of sex hormone binding globulin and testosterone predict the development of non insulin dependent diabetes mellitus in men. Am J Epidemiol. 1996;143:889–897
  24. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women:the Rancho Bernardo Study. Diabetes Care. 2002;25(1):55–60
  25. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27:1036–1041
  26. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB, et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with the development of the metabolic syndrome in non-obese men. J Clin Endocrinol Metab. 2006;91:843–850
  27. Blouin K, Després JP, Couillard C, Tremblay A, Prud’homme D, Bouchard C, et al. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism. 2005;54:1034–1040
  28. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf). 2005;63:239–250
  29. Kapoor D, Aldred H, Clarke S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30:911–917
  30. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, et al. Androgens and diabetes in men. Results from the third national health and nutrition examination survey. Diabetes Care. 2007;30:234–238
  31. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. JCEM. 2006;91:4335–4337
  32. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90:2618–2623
  33. Corona G, Mannucci E, Schulman C, Petrone L, Mansani R, Cilotti A, et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol. 2006;50:595–604
  34. Keating NL, O’Malley J, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456
  35. Yassin E, Saad F, Guillaume A, Heinemann K. Effect of androgen deprivation on glycaemic control and on biochemical cardiovascular risk factors in men with diabetes. J Urol. 2006;175(suppl):385
  36. Svartberg J, von Mühlen D, Mathiesen E, Joakimsen O, Bønaa KH, Stensland-Bugge E, et al. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med. 2006;259(6):576–582
  37. Heufelder A, Gooren L, Saad F et al., Testosterone replacement enhances the favourable effects of exercise and dietary modificationin hypogonadal men with type 2 diabetes. The Endocrine Society's 89th annual meeting program & Absracts 2007;OR-55-5:151.
  38. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35): prospective observational study. BMJ. 2000;321:405–412
  39. Cohen PG. The hypogonadal-obesity cycle. Med Hypotheses. 1999;52:49–51
  40. Isidori AM, Caprio M, Strollo F. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999;84:3673–3680
  41. Stanworth RD, Kapoor D, Channer KS, Jones TH. Testosterone levels correlate positively with HDL cholesterol levels in men with type 2 diabetes. Endocrine Abstracts. 2007;14:P628
  42. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, et al. Effect of testosterone on sexual function in men: results of meta-analysis. Clin Endocrinol (Oxf). 2005;63:239–243
  43. Kratzik CW, Schatzl G, Lunglmayr G, Rücklinger E, Huber J. The impact of age, body mass index and testosterone on erectile dysfunction. J Urol. 2005;174:240–243
  44. Kapoor D, Clarke S, Channer KS, Jones TH. Erectile dysfunction is associated with low testosterone levels and visceral adiposity in men with type 2 diabetes Int. J. Androl. 2007;30:500–507
  45. Esposito K, Giugliano F, Martedì E, Feola G, Marfella R, D’Armiento M, et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care. 2005;28:1201–1203
  46. Gazzaruso C, Giordanetti S, De Amici E, Bertone G, Falcone C, Geroldi D, et al. Relationship between erectile dysfunction and silent myocardial ischaemia in apparently uncomplicated type 2 diabetic patients. Circulation. 2004;110:22–26
  47. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male. 2003;6:94–99
  48. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf). 2003;58:632–638
  49. Shabsigh R, Kaufman J, Steidle J, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172:658–663
  50. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J, et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone therapy alone failed. J Urol. 2003;173:530–532
  51. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, et al EAU Guidelines on erectile dysfunction: An update. Eur Urol. 2006;49:806–815
  52. Jones RD, Nettleship JE, Jones TH, Channer KS. Testosterone and atherosclerosis in aging men: Purported association and clinical implications. Am J Cardiovasc Drugs. 2005;5:141–154
  53. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000;21:890–894
  54. Fukui M, Kitagawa Y, Nakamura N, Kadono M, Mogami S, Hirata C, et al. Association between serum testosterone concentration and carotid atherosclerosis in men with Type 2 diabetes. Diabetes Care. 2003;26:1869–1873
  55. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE, et al. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003;157:25–31
  56. Svartberg J, von Mühlen D, Mathiesen E, Joakimsen O, Bønaa KH, Stensland-Bugge E, et al. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med. 2006;259:576–582
  57. De Pergola G, Pannacciulli N, Ciccone M, Tartagni M, Rizzon P, Giorgino R, et al. Free testosterone plasma levels are negatively associated with the intima-media thickness of the common carotid artery in overweight and obese glucose-tolerant young adult men. Int J Obes Relat Metab Disord. 2003;27:803–807
  58. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J Clin Endocrinol Metab. 2002;87:3632–3639
  59. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109:2074–2079
  60. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis. Circ Res. 1999;84:813–819
  61. Bruck B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C, et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1997;17:2192–2199
  62. Larsen BA, Nordestgaard BG, Stender S, Kjeldsen K. Effect of testosterone on atherogenesis incholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis. 1993;99:79–86
  63. Nettleship JE, Jones TH, Channer KS, Jones RD, Testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect independent of the classical androgen receptor. Circulation In press.
  64. Jones RD, Pugh PJ, Jones TH, Channer KS. The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action. Br J Pharmacol. 2003;138:733–744
  65. Scragg JL, Jones RD, Channer KS, Jones TH, Peers C. Testosterone is a potent inhibitor of L-type Ca2+ channels. Biochim Biophys Res Comm. 2004;318:503–506
  66. Hall J, Jones RD, Jones TH, Channer KS, Peers C. Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology. 2006;147:2675–2680
  67. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone improves functional capacity and symptoms in men with heart failure. Heart. 2004;90:446–447
  68. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J. 2003;24:909–915

PII: S1875-6867(08)00075-4

doi: 10.1016/j.jomh.2008.03.014

journal of men's health
Volume 5 , Pages S26-S34 , September 2008

Article Tools